Levothyroxine Efficacy in Hispanic and Latino Patients: Documented Gaps and Dosing Considerations

Why Levothyroxine Response Differs Across Ethnic Groups

Levothyroxine is the most prescribed medication in the United States, with over 100 million prescriptions dispensed annually. Yet the assumption that a single weight-based dose produces uniform results across all populations is not supported by population-level data. Hispanic and Latino patients show distinct patterns in thyroid hormone metabolism that affect both dose requirements and clinical outcomes.

The TSH Reference Range Problem

The TSH reference ranges used by most U.S. Laboratories (typically 0.45-4.5 mIU/L) were established using data from the NHANES III survey, which included a predominantly non-Hispanic white, iodine-sufficient cohort [1]. A 2002 analysis published in the Journal of Clinical Endocrinology & Metabolism found that TSH distribution curves shift based on ethnicity, with Mexican Americans demonstrating lower median TSH values (1.13 mIU/L) compared to non-Hispanic whites (1.40 mIU/L) [2]. This means a Hispanic patient with a TSH of 3.8 mIU/L might be functionally undertreated despite falling within "normal" range.

Population-Level Screening Gaps

The 2014 American Thyroid Association (ATA) guidelines acknowledge that subclinical hypothyroidism prevalence varies by race and ethnicity but do not provide ethnicity-specific TSH targets [3]. A 2019 cross-sectional study of 14,545 adults in the National Health Interview Survey found that Hispanic adults were 30% less likely to report having had thyroid function testing compared to non-Hispanic white adults, even after adjusting for insurance status and healthcare access [4]. Fewer tests mean later diagnoses and longer periods of untreated hypothyroidism.

Pharmacogenomic Variants That Affect Levothyroxine Metabolism

The conversion of T4 (levothyroxine) to active T3 depends on deiodinase enzymes, principally type 2 deiodinase (DIO2). Genetic variants in the DIO2 gene alter this conversion, and their frequency varies significantly across ethnic populations. Understanding these variants helps explain why some Hispanic patients report persistent symptoms despite "normal" lab values.

The DIO2 Thr92Ala Polymorphism

The most studied variant, DIO2 Thr92Ala (rs225014), reduces the efficiency of T4-to-T3 conversion. A 2009 study by Panicker et al. (N=552) found that patients homozygous for this variant had lower baseline psychological well-being on levothyroxine monotherapy and showed greater improvement when T3 was added [5]. Population frequency data from the 1000 Genomes Project shows that the Ala allele appears in 36-45% of admixed Latin American populations, compared to 33-38% in European-ancestry cohorts [6].

UGT1A and Glucuronidation Differences

Levothyroxine undergoes hepatic glucuronidation via UGT1A enzymes before biliary excretion. The UGT1A1*28 polymorphism (associated with Gilbert syndrome) affects glucuronidation rates and is found at varying frequencies across Hispanic subpopulations. Puerto Rican and Dominican populations carry this variant at rates of 26-39%, while Mexican American populations show frequencies closer to 12-18% [7]. Faster glucuronidation can increase levothyroxine clearance, effectively reducing the active drug available.

CYP3A4 and Drug Interaction Susceptibility

CYP3A4 metabolizes multiple medications co-prescribed with levothyroxine. The CYP3A4*1B variant, which occurs in approximately 9-11% of Mexican Americans compared to 4-5% of European Americans, may alter the metabolism of drugs that compete with or induce levothyroxine clearance [8]. Patients taking rifampin, carbamazepine, or phenytoin alongside levothyroxine require particularly close TSH monitoring.

Insulin Resistance, Obesity, and Levothyroxine Dosing

Hispanic and Latino adults carry a disproportionate burden of metabolic disease. The CDC reports that 17.7% of Hispanic adults have diagnosed diabetes, compared to 10.2% of non-Hispanic white adults [9]. This metabolic context directly affects thyroid hormone pharmacokinetics.

BMI and Dose Requirements

Standard levothyroxine dosing at 1.6 mcg/kg of actual body weight was derived from studies with mean BMIs in the normal-to-overweight range. A 2014 study by Santini et al. Found that patients with BMI >30 kg/m² required 12-15% higher weight-based doses to achieve the same TSH suppression as normal-weight patients [10]. Given that 45.7% of Hispanic adults in the U.S. Have obesity (compared to 41.4% of non-Hispanic white adults), a substantial proportion of Hispanic patients on levothyroxine may be systematically underdosed when clinicians use ideal body weight rather than actual body weight.

Metformin Co-Administration

Metformin, prescribed to roughly 50% of Hispanic adults with type 2 diabetes, lowers TSH levels independently of thyroid function. A 2014 meta-analysis of four studies (N=846) found that metformin reduced TSH by 0.3-0.7 mIU/L in hypothyroid patients on levothyroxine [11]. This can mask true hypothyroidism or falsely suggest adequate dosing. Clinicians should measure free T4 alongside TSH in any patient taking both medications.

The HealthRX Metabolic-Thyroid Assessment Protocol

For Hispanic and Latino patients starting or adjusting levothyroxine, we recommend evaluating four metabolic variables at baseline: fasting insulin, HbA1c, BMI, and concurrent metformin use. Each variable can shift TSH interpretation and dose requirements independently, and they co-occur at high rates in this population.

Absorption Barriers and Formulation Considerations

Levothyroxine is a narrow therapeutic index drug. Small changes in absorption produce clinically meaningful shifts in serum T4 and TSH. Several factors disproportionately common among Hispanic populations can impair absorption.

Dietary Calcium and Iron Intake

Traditional Latin American diets often feature high calcium foods (corn tortillas processed with cal/lime, dairy, beans) and iron-rich preparations. Calcium carbonate reduces levothyroxine absorption by 20-25% when taken within 4 hours of the dose [12]. The ATA recommends separating levothyroxine from calcium supplements by at least 4 hours [3], but dietary calcium from whole foods is harder to time around.

Gastric pH and PPI Use

Levothyroxine tablets require an acidic gastric environment for dissolution. Proton pump inhibitors (PPIs), prescribed at high rates for Hispanic patients with H. Pylori (seroprevalence of 60-70% in some Hispanic subgroups vs. 20-30% in non-Hispanic whites), raise gastric pH and reduce tablet absorption by up to 30% [13]. Liquid levothyroxine formulations (Tirosint-SOL) and soft-gel capsules (Tirosint) bypass this pH dependency entirely, achieving equivalent absorption regardless of gastric acidity [14].

Celiac Disease and Lactose Intolerance

While celiac disease prevalence in Hispanic populations appears similar to general U.S. Rates (approximately 0.5-1%), lactose intolerance affects 50-80% of Hispanic adults [15]. Many branded levothyroxine formulations contain lactose as a filler. Patients with lactose intolerance may experience variable absorption from standard tablets. Tirosint (gel capsule) is lactose-free and gluten-free.

TSH Targets: Should They Be Ethnicity-Specific?

The question of whether TSH reference ranges should vary by ethnicity remains unresolved but increasingly well-supported by data. Using a single universal range risks both overtreatment and undertreatment depending on the patient's background.

Evidence for Lower Normal Ranges

NHANES data consistently show that Mexican American populations have lower TSH distributions than non-Hispanic white populations. A 2007 study by Boucai et al. (N=14,376) found that the 97.5th percentile TSH value for Mexican Americans was 3.7 mIU/L, compared to 4.1 mIU/L for non-Hispanic whites [16]. Applying a universal upper limit of 4.5 mIU/L could leave a subset of Hispanic patients in a biochemically hypothyroid state relative to their population-specific norm.

The ATA Position

The 2014 ATA guidelines note that "TSH reference ranges are influenced by age, sex, ethnicity, and iodine intake" but stop short of recommending population-specific cutoffs [3]. Dr. Elizabeth Pearce, an ATA guideline author, has stated that "the ideal approach would incorporate population-specific reference intervals, but the data to establish these with confidence across all Hispanic subgroups remain insufficient" [3]. The practical implication: clinicians treating Hispanic patients should weigh symptoms alongside TSH values rather than relying on lab numbers alone.

Practical Target Considerations

For Hispanic patients on levothyroxine who report persistent fatigue, weight gain, or cognitive symptoms despite a TSH "within normal limits," targeting a TSH of 1.0-2.5 mIU/L (rather than simply <4.5 mIU/L) aligns more closely with the population-specific distribution data. This is consistent with the Endocrine Society's 2012 recommendation that most treated hypothyroid patients feel best with TSH in the lower half of the reference range [17].

Healthcare Access and Adherence Disparities

Even when the right dose is prescribed, Hispanic patients face structural barriers to achieving and maintaining euthyroidism.

Insurance and Cost

As of 2024, 18.0% of Hispanic adults under age 65 lack health insurance, compared to 6.6% of non-Hispanic white adults [18]. Generic levothyroxine costs $4-15/month without insurance, but the monitoring required (TSH checks every 4-6 weeks during titration, then every 6-12 months) adds $50-200 per lab draw for uninsured patients. Irregular monitoring leads to prolonged periods of suboptimal dosing.

Language and Health Literacy

A 2018 study in Thyroid found that Spanish-speaking patients with hypothyroidism had significantly lower medication adherence rates (68% vs. 84% in English-speaking patients) and were less likely to understand levothyroxine timing requirements (empty stomach, 30-60 minutes before food) [19]. Bilingual patient education materials and pharmacist counseling in Spanish improve adherence by 15-22% in controlled studies [20].

Formulation Switching

State Medicaid programs and pharmacy benefit managers frequently substitute between levothyroxine brands and generics. A 2004 analysis by Hennessey et al. Showed that switching between levothyroxine formulations produced TSH excursions of 0.5-2.0 mIU/L in 30% of patients [21]. The ATA recommends maintaining patients on a consistent formulation and retesting TSH 6 weeks after any involuntary switch [3]. Hispanic patients on Medicaid face higher rates of formulary-driven switches, compounding their risk of unstable dosing.

Clinical Recommendations for Treating Hispanic and Latino Patients

Practical adjustments can narrow the efficacy gap without waiting for population-specific guidelines.

Baseline Assessment

Measure TSH, free T4, free T3, thyroid peroxidase antibodies, fasting insulin, and HbA1c at the initial evaluation. The combination reveals both thyroid status and metabolic context. Document concurrent medications (metformin, PPIs, calcium, iron) that affect levothyroxine pharmacokinetics.

Dose Initiation

Use actual body weight (not ideal body weight) for the 1.6 mcg/kg calculation. For patients with BMI >30 or concurrent insulin resistance, consider starting at 1.8 mcg/kg and titrating to a TSH target of 1.0-2.5 mIU/L. Recheck TSH at 6 weeks.

Formulation Selection

For patients taking PPIs, those with lactose intolerance, or those with erratic absorption patterns, consider Tirosint gel capsules or liquid levothyroxine rather than standard tablets. These formulations reduce one variable in a population already dealing with multiple absorption confounders.

Monitoring Cadence

During titration, check TSH and free T4 every 6 weeks until stable. Once euthyroid, monitor every 6 months for the first 2 years (rather than the standard annual check) to catch drift from formulation switches, dietary changes, or evolving metabolic disease. After 2 stable years, annual monitoring is reasonable.

Patients on levothyroxine plus metformin should have free T4 measured at every check, since metformin's TSH-lowering effect can obscure true thyroid status.